Burkin
Dr. Dean J. Burkin, Founder and CEO is a world expert on the role integrins and laminin play in muscle disease. Dr. Burkin was the first to show the alpha7beta1 integrin can serve as a surrogate for the loss of dystrophin in DMD. Dr. Burkin led pioneering studies to show laminin-111 protein can substitute for the loss of merosin in MDC1A. Dr. Burkin has identified protein and small molecule therapeutics which have been patented for the treatment of muscular dystrophy.

Dr. Dean Burkin received his B.Sc. (1st class Hons) in Developmental Biology and Genetics from Victoria University of Wellington, New Zealand and Ph.D. in Biochemistry and Genetics from the University of Colorado, USA. Dr. Burkin completed postdoctoral training in Genetics, Cell and Molecular Biology at Cambridge University, England and University of Illinois at Urbana-Champaign.


Wuebbles
Dr. Ryan D. Wuebbles, Co-Founder and CSO is responsible for overseeing the Research and Development (R&D) at Strykagen. He has been an integral part of developing Strykagen’s core technologies and is co-inventor on the patented technologies licensed by Strykagen. He has research experience across a broad range of topics including biochemistry, drug development, molecular biology, genetic analysis, DNA engineering, and animal model development.

Dr. Ryan Wuebbles received his B.Sc. in Chemistry and later a Ph.D. in Cell and Developmental Biology from the University of Illinois at Urbana-Champaign. His thesis research focused mainly on developmental muscle biology and its relation to FacioScapuloHumeral Dystrophy (FSHD).

Van Ry
Dr. Pam Van Ry, Senior Scientist is responsible for projects involving protein therapeutics for the treatment of muscular dystrophy and biomarker development. Pam Van Ry has been instrumental in the identification, purification and preclinical testing of Stryka-Pro1 as a novel small protein therapy for the treatment of Duchenne muscular dystrophy. Pam Van Ry has experience in cell and molecular biology including culturing human muscle cells, protein isolation, miRNA analysis and preclinical studies using models of muscular dystrophy.

Dr. Pam Van Ry received her B.Sc. in Chemistry from the University of Nevada, Reno and Ph.D. in Cellular and Molecular Pharmacology and Physiology from the University of Nevada, Reno in 2014.

Maine
David A. Maine, CFO oversees the business operations of Strykagen’s suite of therapeutic products for the treatment of the muscular dystrophies. With more than 15 years of managerial experience, Mr. Maine is involved in the commercialization of Strykagen’s technologies. Mr. Maine has experience with Federal grants contracts, governmental accounting practices, community relations, economic development, market research, business planning, and policy analysis.

Mr. David Maine received his BS in Env. Resource Economics at the University of Nevada, Reno and MA in Economics from the University of Nevada, Reno College of Business in 2014.

Apurva
Apurva Sarathy, Research Officer is responsible for the coordinating research and commercialization of Strykagen’s product line for the treatment of muscular dystrophy. Ms. Sarathy has experience in drug development and preclinical studies using models of DMD and MDC1A. Ms. Sarathy works closely with Mr. David Maine to align Strykagen’s therapeutics with commercialization and business development.

Ms. Sarathy received her BS in neurobiology and MS in Exercise Physiology from the University of Texas. Currently Ms. Sarathy is a graduate student in the Cell and Molecular Biology Program at the University of Nevada, Reno and is working on developing therapeutics for the muscular dystrophies. Ms. Sarathy is expected to graduate with a PhD in Cell and Molecular Biology in 2015.

Apurva
Ashley Tarchione, Communication and Research Intern is responsible for coordinating research and communication on Strykagen’s product pipeline for the treatment of rare muscle diseases. Ms. Tarchione works closely with Ms. Sarathy and has conducted preclinical studies developing Strykagen’s therapeutics for the treatment of DMD and MDC1A.

Ms. Tarchione is currently pursing a degree in Neuroscience with minors in Biochemistry and Political Science at the University of Nevada, Reno. She expects to graduate in Spring of 2016 and pursue an MD-PhD.


Scientific Advisors:

Dr. Rachelle Crosbie-Watson
Professor, Dept. Integrative Biology & Physiology
University of California
Los Angeles, CA 90095

Dr. Peter Jones
Associate Professor, Dept. Cell and Developmental Biology
University of Massachusetts Medical School
55 Lake Avenue
Worcester MA 01655

Business Advisors:

Dr. Mick Hitchcock, PhD
Senior Advisor
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404